Project 2: Strategies for Reducing Nicotine Content in Cigarettes
研究概览
地位
详细说明
研究类型
注册 (预期的)
阶段
- 不适用
联系人和位置
学习地点
-
-
Arizona
-
Phoenix、Arizona、美国、85054
- Mayo Clinic
-
-
California
-
San Francisco、California、美国、94143
- University of California San Francisco
-
-
Florida
-
Tampa、Florida、美国、33617
- Moffitt Cancer Center
-
-
Maryland
-
Baltimore、Maryland、美国、21224
- Johns Hopkins University
-
-
Minnesota
-
Duluth、Minnesota、美国、55812
- University of Minnesota Medical School Duluth
-
Minneapolis、Minnesota、美国、55455
- University of Minnesota
-
-
North Carolina
-
Durham、North Carolina、美国、27705
- Duke University
-
-
Oregon
-
Eugene、Oregon、美国、97403
- Oregon Research Institute
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、美国、19104
- University of Pennsylvania
-
-
Texas
-
Houston、Texas、美国、77030
- MDAnderson Cancer Center
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Age 18+
- Daily smokers who smoke an average of at least five cigarettes per day for at least 1 year
- Breath CO levels > 8 ppm (if ≤ 8 ppm, then NicAlert Strip level must indicate regular smoking)
Exclusion Criteria:
- Planned quit date in the next 30 days
- Currently seeking treatment for smoking cessation
- Currently using nicotine replacement therapies or other pharmacotherapies as cessation aid (non-cessation intermittent use acceptable)
- A quit attempt in the past 30 days resulting in greater than 3 days of abstinence
- Using other tobacco products or e-cigarettes more than 9 days in the past 30 days
- Significant unstable medical conditions (Any significant change in a serious medical condition occurring during the past 3 months including, cardiovascular disease, COPD, and cancer, as determined by the licensed medical professional at each site)
- Unstable psychiatric conditions (Any significant change in psychiatric symptoms during the past 3 months as determined by the licensed medical professional at each site)
- Schizophrenia and schizoaffective disorder
- Psychiatric medication changes (e.g., new prescriptions, changes in dosages, or discontinuation of medications) in the past 3 months that was a result of negative changes in symptoms.
Positive toxicology screen for any of the following drugs: cocaine, opiates, methadone, benzodiazepines, barbiturates, amphetamines, methamphetamines, and PCP
- Marijuana will be tested for but will not be an exclusionary criterion.
- Participants with valid prescriptions for opiates, benzodiazepines, barbiturates, amphetamines or methadone will not be excluded.
- Participants failing the toxicology screen will be allowed to re-screen once.
Blood alcohol level > 0.01
a. Participants failing the blood alcohol screen will be allowed to re-screen once.
- Binge drinking alcohol (more than 9 days in the past 30 days, 4/5 drinks per day (female/male))
- Pregnant, trying to become pregnant or breastfeeding
- Predominant use of 'roll your own cigarettes'
- CO reading >80 ppm
Systolic BP greater than or equal to 160
a. Participants failing for blood pressure will be allowed to re-screen once.
Diastolic BP greater than or equal to 100
a. Participants failing for blood pressure will be allowed to re-screen once.
Systolic BP below 90 and symptomatic (dizziness, extreme fatigue, difficulty thinking, inability to stand or walk, feeling faint)
a. Participants failing for blood pressure will be allowed to re-screen once.
Diastolic BP below 50 and symptomatic (dizziness, extreme fatigue, difficulty thinking, inability to stand or walk, feeling faint)
a. Participants failing for blood pressure will be allowed to re-screen once.
Heart rate greater than or equal to 105 bpm
a. Participants failing for heart rate will be allowed to re-screen once.
Heart rate lower than 45 bpm and symptomatic (dizziness, extreme fatigue, difficulty thinking, inability to stand or walk, feeling faint)
a. Participants failing for heart rate will be allowed to re-screen once.
- Indicating any suicidal ideation in the past month, suicide attempts in the past 5 years (if within past 5 to 10 years, requires physician approval), or score of >4 on the MINI suicide subscale
- Household member enrolled in the study concurrently.
- Inability to independently read and comprehend the consent form and other written study materials and measures because participants are required to complete parts of the protocol at home independently.
- Participated in prior study that involved reduced nicotine content cigarettes.
- Having participated in a research study during the past three months in a study that would impact baseline smoking or response to study products.
Currently taking the following anticonvulsant medications:
- Phenytoin [Brand Name: Dilantin]
- Carbamazepine [Brand Name: Tegretol, Carbatrol, Equetro, Epitol]
- Oxcarbazepine [Brand Name: Trileptal]
- Primidone [Brand Name: Mysoline]
- Phenobarbital
Currently taking the following medication:
- Bendamustine (Treanda)
- Clopidogrel (Plavix)
- Clozapine (Clozaril, FazaClo)
- Erlotinib (Tarceva)
- Flecainide (Tambocor)
- Fluvoxamine (Luvox)
- Irinotecan (Camptosar)
- Olanzapine (Zyprexa)
- Ropinirole (Requip)
- Tacrine (Cognex)
- Theophylline (Theo Dur, etc.)
学习计划
研究是如何设计的?
设计细节
- 主要用途:基础科学
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:Normal Nicotine Control Group
These subjects will smoke normal nicotine content Spectrum brand cigarettes for 20 weeks.
|
Participants will smoke experimental cigarettes for a period of 20-weeks.
|
|
实验性的:Immediate Nicotine Reduction Group
This group will immediately be switched to smoking very low nicotine content (VLNC) Spectrum brand cigarettes.
They will smoke these cigarettes for 20 weeks.
|
Participants will smoke experimental cigarettes for a period of 20-weeks.
|
|
实验性的:Gradual Nicotine Reduction Group
This group will smoke progressively lower nicotine content Spectrum brand cigarettes for a period of one month each until they end up smoking the same VLNC cigarettes as the immediate reduction group.
|
Participants will smoke experimental cigarettes for a period of 20-weeks.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Toxicant exposure pattern: Expired air carbon monoxide
大体时间:20-week treatment period
|
Between group comparison of expired air carbon monoxide (CO) values at week 20 using baseline CO values as a covariate.
|
20-week treatment period
|
|
Toxicant exposure pattern: Urinary phenanthrene tetroal (Phe)
大体时间:20-week treatment period
|
Between group comparison of urinary phenanthrene tetroal values at week 20 using baseline values as a covariate.
|
20-week treatment period
|
|
Toxicant exposure pattern: Urinary mercapturic acids of acrolein
大体时间:20-week treatment period
|
Between group comparison of urinary mercapturic acid level at week 20 using baseline values as a covariate.
|
20-week treatment period
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Nicotine exposure: Total nicotine equivalents (TNE)
大体时间:End of treatment (Week 20)
|
Between group comparison of urinary total nicotine equivalents at week 20 using baseline values as a covariate.
|
End of treatment (Week 20)
|
|
Other toxicant exposure: Tobacco specific nitrosamines-Total NNAL and NNN
大体时间:End of treatment (Week 20)
|
Between group comparison of urinary total NNAL and NNN levels at week 20 using baseline values as a covariate.
|
End of treatment (Week 20)
|
|
Effect biomarker: C-Reactive protein-high sensitivity as an inflammation biomarker
大体时间:End of treatment (Week 20)
|
Between group comparison of C-Reactive protein levels in serum at week 20 using baseline values as a covariate.
|
End of treatment (Week 20)
|
|
Measure of acceptability: Retention in study
大体时间:End of treatment (Week 20)
|
Between group comparison of early termination from the study.
|
End of treatment (Week 20)
|
|
Measure of acceptability: Non-compliance
大体时间:End of treatment (Week 20)
|
Between group comparison of use of non-study tobacco products.
|
End of treatment (Week 20)
|
|
Effect biomarker: 8-epi-PGF2α as a biomarker for oxidative stress
大体时间:End of treatment (Week 20)
|
Between group comparison of 8-epi-PGF2α at week 20 using baseline values as a covariate.
|
End of treatment (Week 20)
|
|
Effect biomarker: White blood cells count as inflammation biomarker
大体时间:End of treatment (Week 20)
|
Between group comparison of white blood cell count at week 20 using baseline values as a covariate.
|
End of treatment (Week 20)
|
|
Nicotine exposure: Urinary cotinine
大体时间:End of treatment (Week 20)
|
Between group comparison of urinary total nicotine equivalents at week 20 using baseline values as a covariate.
|
End of treatment (Week 20)
|
合作者和调查者
调查人员
- 首席研究员:Eric Donny, PhD、University of Pittsburgh
出版物和有用的链接
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.